RYTM Rhythm Pharmaceuticals Inc.

23.73
+0.81  (+4%)
Previous Close 22.93
Open 23.31
Price To Book 3.71
Market Cap 817,247,484
Shares 34,432,167
Volume 3,786
Short Ratio
Av. Daily Volume 108,760

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 additional data due 2020.
Setmelanotide
POMC Heterozygous Deficiency Obesity, Alstrom Syndrome, POMC Epigenetic Disorders
Phase 3 data due 2020.
Setmelanotide
Alstrom Syndrome and Bardet-Biedl Syndrome
Phase 3 top-line data due 3Q 2019.
Setmelanotide
Leptin Receptor Deficiency Obesity
Phase 3 initial data due 3Q 2019.
Setmelanotide
POMC deficiency obesity

Latest News

  1. Rhythm Pharmaceuticals Announces Election of Jennifer Good to its Board of Directors
  2. Rhythm Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference
  3. Here’s What Hedge Funds Think About Rhythm Pharmaceuticals, Inc. (RYTM)
  4. Rhythm Pharmaceuticals to Present at Bank of America Merrill Lynch 2019 Health Care Conference
  5. Rhythm Pharmaceuticals Reports First Quarter 2019 Financial Results
  6. If You Had Bought Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock A Year Ago, You Could Pocket A 10% Gain Today
  7. Rhythm Pharmaceuticals to Present at 18th Annual Needham Healthcare Conference
  8. Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders
  9. Rhythm Pharmaceuticals Announces Promising Clinical Data in MC4R Pathway Heterozygous Obesity and Strategy for Further Development
  10. Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
  11. Rhythm Pharmaceuticals to Present at Cowen & Co. 39th Annual Health Care Conference
  12. Recent Analysis Shows Alexion Pharmaceuticals, Plug Power, Rayonier Advanced Materials, SunCoke Energy, Rhythm Pharmaceuticals, and Armstrong Flooring Market Influences — Renewed Outlook, Key Drivers of Growth
  13. A Look At The Fair Value Of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
  14. Rhythm Pharmaceuticals to Outline Expected 2019 Milestones and Review Updated Clinical Data in Bardet-Biedl Syndrome at 37th Annual J.P. Morgan Healthcare Conference
  15. Rhythm Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes
  16. Rhythm Pharmaceuticals to Host Key Opinion Leader Symposium on MC4R Pathway and Patient Experience with Rare Genetic Disorders of Obesity, Including Bardet-Biedl Syndrome
  17. Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Alström Syndrome at ObesityWeek 2018
  18. Rhythm Pharmaceuticals Reports Third Quarter 2018 Financial Results
  19. Rhythm Pharmaceuticals to Present at Stifel 2018 Healthcare Conference